Slate Medicines Overview
- Year Founded
-
2025
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
PIPE
- (Announced)
- Latest Deal Amount
-
$245M
- Investors
-
8
Slate Medicines General Information
Description
Slate Medicines Inc is a biotechnology company focused on developing novel therapeutics aimed at treating migraine and headache disorders. Its initial pipeline includes therapeutics targeting pituitary adenylate cyclase activating peptide (PACAP) and vasoactive intestinal peptide (VIP), two neuropeptides that share common signaling pathways and are implicated in migraine pathophysiology.
Contact Information
Website
www.slatemedicines.comCorporate Office
- 200 Berkeley Street
- 18th Floor
- Boston, MA 02116
- United States
Corporate Office
- 200 Berkeley Street
- 18th Floor
- Boston, MA 02116
- United States
Slate Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. PIPE | 17-Aug-2026 | $245M | Announced | Clinical Trials - Phase 1 | ||
| 3. Reverse Merger | 17-Aug-2026 | Announced | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 24-Feb-2026 | $130M | $133M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | $3M | $3M | Completed | Clinical Trials - Phase 1 |
Slate Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Slate Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Slate Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Slate Medicines Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Forbion | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| RA Capital Management | Asset Manager | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Frazier Lifesciences Acquisition | Special Purpose Acquisition Company (SPAC) | Minority |
Slate Medicines Acquisitions (1)
Slate Medicines’s most recent deal was a Merger/Acquisition with Fulcrum Therapeutics. The deal was made on 16-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Fulcrum Therapeutics | 16-Aug-2026 | Merger/Acquisition | Drug Discovery |
Slate Medicines FAQs
-
When was Slate Medicines founded?
Slate Medicines was founded in 2025.
-
Where is Slate Medicines headquartered?
Slate Medicines is headquartered in Boston, MA.
-
What is the size of Slate Medicines?
Slate Medicines has 9 total employees.
-
What industry is Slate Medicines in?
Slate Medicines’s primary industry is Biotechnology.
-
Is Slate Medicines a private or public company?
Slate Medicines is a Private company.
-
What is Slate Medicines’s current revenue?
The current revenue for Slate Medicines is .
-
How much funding has Slate Medicines raised over time?
Slate Medicines has raised $133M.
-
Who are Slate Medicines’s investors?
Forbion, Foresite Capital, RA Capital Management, Deep Track Capital, and Frazier Lifesciences Acquisition are 5 of 8 investors who have invested in Slate Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
